Key clinical point: Colchicine use in patients with gout is associated with a lower risk for type 2 diabetes mellitus (T2D).
Major finding: Colchicine users vs. nonusers had a lower cumulative incidence of T2D (18.8% vs. 25.0%) and a significantly lower risk for T2D (adjusted hazard ratio 0.74; 95% CI 0.36-0.87), with the inverse association remaining significant across both sexes and different age groups.
Study details: The data come from a retrospective cohort study including patients newly diagnosed with gout who used (n = 3841) and did not use (n = 7682) colchicine.
Disclosures: The study received no external funding. The authors declared no conflict of interests.
Source: Chu C-C et al. Association between clinical use of colchicine and risk of type 2 diabetes mellitus among gouty patients: A nationwide cohort study. Int J Environ Res Public Health. 2022;19(6):3395 (Mar 14). Doi: 10.3390/ijerph19063395